These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Delaware
|
|
51-0014090
|
|
(State or other Jurisdiction of
|
|
(I.R.S. Employer
|
|
Incorporation or Organization)
|
|
Identification No.)
|
|
Large Accelerated Filer
x
|
|
Accelerated Filer
o
|
|
|
|
|
|
Non-Accelerated Filer
o
|
|
Smaller reporting company
o
|
|
|
|
|
|
Page
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
Item 1.
|
CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
Three Months Ended
|
|||||
|
|
March 31,
|
|||||
|
|
2012
|
2011
|
||||
|
Net sales
|
$
|
11,230
|
|
$
|
10,034
|
|
|
Other income, net
|
26
|
|
25
|
|
||
|
Total
|
11,256
|
|
10,059
|
|
||
|
Cost of goods sold and other operating charges
|
7,527
|
|
6,831
|
|
||
|
Selling, general and administrative expenses
|
1,169
|
|
1,027
|
|
||
|
Research and development expense
|
505
|
|
399
|
|
||
|
Interest expense
|
114
|
|
100
|
|
||
|
Total
|
9,315
|
|
8,357
|
|
||
|
Income before income taxes
|
1,941
|
|
1,702
|
|
||
|
Provision for income taxes
|
441
|
|
258
|
|
||
|
Net income
|
1,500
|
|
1,444
|
|
||
|
Less: Net income attributable to noncontrolling interests
|
12
|
|
13
|
|
||
|
Net income attributable to DuPont
|
$
|
1,488
|
|
$
|
1,431
|
|
|
Basic earnings per share of common stock
|
$
|
1.59
|
|
$
|
1.54
|
|
|
Diluted earnings per share of common stock
|
$
|
1.57
|
|
$
|
1.52
|
|
|
Dividends per share of common stock
|
$
|
0.41
|
|
$
|
0.41
|
|
|
|
Three Months Ended
|
|||||
|
|
March 31,
|
|||||
|
|
2012
|
2011
|
||||
|
Net income
|
$
|
1,500
|
|
$
|
1,444
|
|
|
Other comprehensive income (loss), before tax:
|
|
|
||||
|
Cumulative translation adjustment
|
170
|
|
44
|
|
||
|
Net revaluation and clearance of cash flow hedges to earnings:
|
|
|
||||
|
Additions and revaluations of derivatives designated as cash flow hedges
|
(2
|
)
|
8
|
|
||
|
Clearance of hedge results to earnings
|
(32
|
)
|
27
|
|
||
|
Net revaluation and clearance of cash flow hedges to earnings
|
(34
|
)
|
35
|
|
||
|
Pension benefit plans:
|
|
|
||||
|
Net loss
|
(23
|
)
|
—
|
|
||
|
Prior service cost
|
22
|
|
—
|
|
||
|
Reclassifications to net income:
|
|
|
||||
|
Amortization of prior service cost
|
4
|
|
4
|
|
||
|
Amortization of loss
|
219
|
|
153
|
|
||
|
Pension benefit plans, net
|
222
|
|
157
|
|
||
|
Other benefit plans:
|
|
|
||||
|
Reclassifications to net income:
|
|
|
||||
|
Amortization of prior service benefit
|
(30
|
)
|
(30
|
)
|
||
|
Amortization of loss
|
22
|
|
15
|
|
||
|
Other benefit plans, net
|
(8
|
)
|
(15
|
)
|
||
|
Net unrealized gain on securities
|
1
|
|
1
|
|
||
|
Other comprehensive income, before tax
|
351
|
|
222
|
|
||
|
Income tax expense related to items of other comprehensive income
|
(64
|
)
|
(62
|
)
|
||
|
Other comprehensive income, net of tax
|
287
|
|
160
|
|
||
|
Comprehensive income
|
1,787
|
|
1,604
|
|
||
|
Less: Comprehensive income attributable to noncontrolling interests
|
14
|
|
12
|
|
||
|
Comprehensive income attributable to DuPont
|
$
|
1,773
|
|
$
|
1,592
|
|
|
|
March 31,
2012 |
December 31,
2011 |
||||
|
Assets
|
|
|
|
|
||
|
Current assets
|
|
|
|
|
||
|
Cash and cash equivalents
|
$
|
3,410
|
|
$
|
3,586
|
|
|
Marketable securities
|
191
|
|
433
|
|
||
|
Accounts and notes receivable, net
|
8,626
|
|
6,022
|
|
||
|
Inventories
|
6,616
|
|
7,195
|
|
||
|
Prepaid expenses
|
260
|
|
151
|
|
||
|
Deferred income taxes
|
706
|
|
671
|
|
||
|
Total current assets
|
19,809
|
|
18,058
|
|
||
|
Property, plant and equipment, net of accumulated depreciation
(March 31, 2012 - $19,695; December 31, 2011 - $19,349)
|
13,395
|
|
13,412
|
|
||
|
Goodwill
|
5,443
|
|
5,413
|
|
||
|
Other intangible assets
|
5,410
|
|
5,413
|
|
||
|
Investment in affiliates
|
1,121
|
|
1,117
|
|
||
|
Deferred income taxes
|
4,052
|
|
4,067
|
|
||
|
Other assets
|
993
|
|
1,012
|
|
||
|
Total
|
$
|
50,223
|
|
$
|
48,492
|
|
|
Liabilities and Equity
|
|
|
|
|
||
|
Current liabilities
|
|
|
|
|
||
|
Accounts payable
|
$
|
4,180
|
|
$
|
4,816
|
|
|
Short-term borrowings and capital lease obligations
|
3,593
|
|
817
|
|
||
|
Income taxes
|
585
|
|
255
|
|
||
|
Other accrued liabilities
|
4,178
|
|
5,297
|
|
||
|
Total current liabilities
|
12,536
|
|
11,185
|
|
||
|
Long-term borrowings and capital lease obligations
|
11,232
|
|
11,736
|
|
||
|
Other liabilities
|
14,935
|
|
15,508
|
|
||
|
Deferred income taxes
|
1,093
|
|
1,001
|
|
||
|
Total liabilities
|
39,796
|
|
39,430
|
|
||
|
Commitments and contingent liabilities
|
|
|
|
|
||
|
Stockholders’ equity
|
|
|
|
|
||
|
Preferred stock
|
237
|
|
237
|
|
||
|
Common stock, $0.30 par value; 1,800,000,000 shares authorized;
Issued at March 31, 2012 - 1,023,888,000; December 31, 2011 - 1,013,164,000
|
307
|
|
304
|
|
||
|
Additional paid-in capital
|
10,086
|
|
10,107
|
|
||
|
Reinvested earnings
|
14,522
|
|
13,422
|
|
||
|
Accumulated other comprehensive loss
|
(8,465
|
)
|
(8,750
|
)
|
||
|
Common stock held in treasury, at cost
(87,041,000 shares at March 31, 2012 and December 31, 2011)
|
(6,727
|
)
|
(6,727
|
)
|
||
|
Total DuPont stockholders’ equity
|
9,960
|
|
8,593
|
|
||
|
Noncontrolling interests
|
467
|
|
469
|
|
||
|
Total equity
|
10,427
|
|
9,062
|
|
||
|
Total
|
$
|
50,223
|
|
$
|
48,492
|
|
|
|
Three Months Ended
|
|||||
|
|
March 31,
|
|||||
|
|
2012
|
2011
|
||||
|
Operating activities
|
|
|
|
|
||
|
Net income
|
$
|
1,500
|
|
$
|
1,444
|
|
|
Adjustments to reconcile net income to cash used for operating activities:
|
|
|
|
|
||
|
Depreciation
|
349
|
|
294
|
|
||
|
Amortization of intangible assets
|
106
|
|
67
|
|
||
|
Contributions to pension plans
|
(614
|
)
|
(105
|
)
|
||
|
Other noncash charges and credits - net
|
311
|
|
385
|
|
||
|
Change in operating assets and liabilities - net
|
(3,529
|
)
|
(3,569
|
)
|
||
|
Cash used for operating activities
|
(1,877
|
)
|
(1,484
|
)
|
||
|
|
|
|
||||
|
Investing activities
|
|
|
|
|
||
|
Purchases of property, plant and equipment
|
(301
|
)
|
(323
|
)
|
||
|
Investments in affiliates
|
(2
|
)
|
(12
|
)
|
||
|
Proceeds from sales of assets - net of cash sold
|
4
|
|
7
|
|
||
|
Net decrease in short-term financial instruments
|
248
|
|
1,585
|
|
||
|
Forward exchange contract settlements
|
(87
|
)
|
(210
|
)
|
||
|
Change in restricted cash
|
—
|
|
(1,991
|
)
|
||
|
Other investing activities - net
|
(18
|
)
|
(21
|
)
|
||
|
Cash used for investing activities
|
(156
|
)
|
(965
|
)
|
||
|
|
|
|
||||
|
Financing activities
|
|
|
|
|
||
|
Dividends paid to stockholders
|
(386
|
)
|
(383
|
)
|
||
|
Net increase in borrowings
|
2,278
|
|
1,991
|
|
||
|
Prepayment / Repurchase of common stock
|
(400
|
)
|
(272
|
)
|
||
|
Proceeds from exercise of stock options
|
389
|
|
605
|
|
||
|
Other financing activities - net
|
(36
|
)
|
(12
|
)
|
||
|
Cash provided by financing activities
|
1,845
|
|
1,929
|
|
||
|
Effect of exchange rate changes on cash
|
12
|
|
53
|
|
||
|
Decrease in cash and cash equivalents
|
$
|
(176
|
)
|
$
|
(467
|
)
|
|
Cash and cash equivalents at beginning of period
|
3,586
|
|
4,263
|
|
||
|
Cash and cash equivalents at end of period
|
$
|
3,410
|
|
$
|
3,796
|
|
|
|
Three Months Ended
|
|||||
|
|
March 31,
|
|||||
|
|
2012
|
2011
|
||||
|
Cozaar
®
/Hyzaar
®
income
|
$
|
25
|
|
$
|
48
|
|
|
Royalty income
|
41
|
|
31
|
|
||
|
Interest income
|
23
|
|
28
|
|
||
|
Equity in earnings of affiliates, excluding exchange gains/losses
|
10
|
|
48
|
|
||
|
Net gain on sales of assets
|
5
|
|
6
|
|
||
|
Net exchange losses
1
|
(80
|
)
|
(143
|
)
|
||
|
Miscellaneous income and expenses, net
2
|
2
|
|
7
|
|
||
|
Total
|
$
|
26
|
|
$
|
25
|
|
|
1
|
The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The net pre-tax exchange gains and losses are recorded in other income, net and the related tax impact is recorded in provision for income taxes on the interim Consolidated Income Statements.
|
|
2
|
Miscellaneous income and expenses, net, generally includes interest items, insurance recoveries, litigation settlements and other items.
|
|
|
Three Months Ended
|
|||||
|
|
March 31,
|
|||||
|
|
2012
|
2011
|
||||
|
Numerator:
|
|
|
||||
|
Net income attributable to DuPont
|
$
|
1,488
|
|
$
|
1,431
|
|
|
Preferred dividends
|
(3
|
)
|
(3
|
)
|
||
|
Net income available to common stockholders
|
$
|
1,485
|
|
$
|
1,428
|
|
|
|
|
|
||||
|
Denominator:
|
|
|
||||
|
Weighted-average number of common shares outstanding - Basic
|
933,910,000
|
|
924,897,000
|
|
||
|
Dilutive effect of the company’s employee compensation plans
|
10,328,000
|
|
16,012,000
|
|
||
|
Weighted-average number of common shares outstanding - Diluted
|
944,238,000
|
|
940,909,000
|
|
||
|
|
Three Months Ended
|
|||
|
|
March 31,
|
|||
|
|
2012
|
2011
|
||
|
Average number of stock options
|
10,724,000
|
|
—
|
|
|
|
March 31,
2012 |
December 31,
2011 |
||||
|
Finished products
|
$
|
4,497
|
|
$
|
4,541
|
|
|
Semifinished products
|
1,796
|
|
2,293
|
|
||
|
Raw materials, stores and supplies
|
1,239
|
|
1,262
|
|
||
|
|
7,532
|
|
8,096
|
|
||
|
Adjustment of inventories to a last-in, first-out (LIFO) basis
|
(916
|
)
|
(901
|
)
|
||
|
Total
|
$
|
6,616
|
|
$
|
7,195
|
|
|
|
March 31, 2012
|
December 31, 2011
|
||||||||||||||||
|
|
Gross
|
Accumulated
Amortization
|
Net
|
Gross
|
Accumulated
Amortization
|
Net
|
||||||||||||
|
Intangible assets subject to amortization (Definite-lived):
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Customer lists
|
$
|
1,859
|
|
$
|
(248
|
)
|
$
|
1,611
|
|
$
|
1,841
|
|
$
|
(220
|
)
|
$
|
1,621
|
|
|
Patents
|
514
|
|
(84
|
)
|
430
|
|
518
|
|
(77
|
)
|
441
|
|
||||||
|
Purchased and licensed technology
|
1,920
|
|
(934
|
)
|
986
|
|
1,854
|
|
(878
|
)
|
976
|
|
||||||
|
Trademarks
|
57
|
|
(26
|
)
|
31
|
|
57
|
|
(25
|
)
|
32
|
|
||||||
|
Other
1
|
326
|
|
(149
|
)
|
177
|
|
330
|
|
(151
|
)
|
179
|
|
||||||
|
|
4,676
|
|
(1,441
|
)
|
3,235
|
|
4,600
|
|
(1,351
|
)
|
3,249
|
|
||||||
|
|
|
|
|
|
|
|
||||||||||||
|
Intangible assets not subject to amortization(Indefinite-lived):
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
In-process research and development
|
70
|
|
—
|
|
70
|
|
70
|
|
—
|
|
70
|
|
||||||
|
Microbial cell factories
2
|
306
|
|
—
|
|
306
|
|
306
|
|
—
|
|
306
|
|
||||||
|
Pioneer germplasm
3
|
975
|
|
—
|
|
975
|
|
975
|
|
—
|
|
975
|
|
||||||
|
Trademarks/tradenames
|
824
|
|
—
|
|
824
|
|
813
|
|
—
|
|
813
|
|
||||||
|
|
2,175
|
|
—
|
|
2,175
|
|
2,164
|
|
—
|
|
2,164
|
|
||||||
|
Total
|
$
|
6,851
|
|
$
|
(1,441
|
)
|
$
|
5,410
|
|
$
|
6,764
|
|
$
|
(1,351
|
)
|
$
|
5,413
|
|
|
1
|
Primarily consists of sales and grower networks, marketing and manufacturing alliances and noncompetition agreements.
|
|
2
|
Microbial cell factories, derived from natural microbes, are used to sustainably produce enzymes, peptides and chemicals using natural metabolic processes. The company recognized the microbial cell factories as an intangible asset upon the acquisition of Danisco. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.
|
|
3
|
Pioneer germplasm is the pool of genetic source material and body of knowledge gained from the development and delivery stage of plant breeding. The company recognized germplasm as an intangible asset upon the acquisition of Pioneer. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.
|
|
|
Short-Term
|
Long-Term
|
Total
|
||||||
|
Obligations for customers and suppliers
1
:
|
|
|
|
|
|
|
|||
|
Bank borrowings (terms up to 5 years)
|
$
|
243
|
|
$
|
80
|
|
$
|
323
|
|
|
Obligations for equity affiliates
2
:
|
|
|
|
|
|
|
|||
|
Bank borrowings (terms up to 2 years)
|
201
|
|
2
|
|
203
|
|
|||
|
Total obligations for customers, suppliers and equity affiliates
|
444
|
|
82
|
|
526
|
|
|||
|
Obligations for divested subsidiaries (terms up to 6 years)
|
16
|
|
4
|
|
20
|
|
|||
|
Total
|
$
|
460
|
|
$
|
86
|
|
$
|
546
|
|
|
1
|
Existing guarantees for customers and suppliers arose as part of contractual agreements.
|
|
2
|
Existing guarantees for equity affiliates arose for liquidity needs in normal operations.
|
|
|
Three Months Ended
|
Three Months Ended
|
||||||||||||||||
|
|
March 31, 2012
|
March 31, 2011
|
||||||||||||||||
|
|
Pre-Tax
|
Tax
|
After-Tax
|
Pre-Tax
|
Tax
|
After-Tax
|
||||||||||||
|
Cumulative translation adjustment
|
$
|
170
|
|
$
|
—
|
|
$
|
170
|
|
$
|
44
|
|
$
|
—
|
|
$
|
44
|
|
|
Net revaluation and clearance of cash flow hedges to earnings:
|
|
|
|
|
|
|
||||||||||||
|
Additions and revaluations of derivatives designated as cash flow hedges
|
(2
|
)
|
—
|
|
(2
|
)
|
8
|
|
(3
|
)
|
5
|
|
||||||
|
Clearance of hedge results to earnings
|
(32
|
)
|
13
|
|
(19
|
)
|
27
|
|
(11
|
)
|
16
|
|
||||||
|
Net revaluation and clearance of cash flow hedges to earnings
|
(34
|
)
|
13
|
|
(21
|
)
|
35
|
|
(14
|
)
|
21
|
|
||||||
|
Pension benefit plans:
|
|
|
|
|
|
|
||||||||||||
|
Net loss
|
(23
|
)
|
3
|
|
(20
|
)
|
—
|
|
—
|
|
—
|
|
||||||
|
Prior service cost
|
22
|
|
(7
|
)
|
15
|
|
—
|
|
—
|
|
—
|
|
||||||
|
Amortization of prior service cost
|
4
|
|
(1
|
)
|
3
|
|
4
|
|
(1
|
)
|
3
|
|
||||||
|
Amortization of loss
|
219
|
|
(75
|
)
|
144
|
|
153
|
|
(53
|
)
|
100
|
|
||||||
|
Pension benefit plans, net
|
222
|
|
(80
|
)
|
142
|
|
157
|
|
(54
|
)
|
103
|
|
||||||
|
Other benefit plans:
|
|
|
|
|
|
|
||||||||||||
|
Amortization of prior service benefit
|
(30
|
)
|
11
|
|
(19
|
)
|
(30
|
)
|
11
|
|
(19
|
)
|
||||||
|
Amortization of loss
|
22
|
|
(8
|
)
|
14
|
|
15
|
|
(5
|
)
|
10
|
|
||||||
|
Other benefit plans, net
|
(8
|
)
|
3
|
|
(5
|
)
|
(15
|
)
|
6
|
|
(9
|
)
|
||||||
|
Net unrealized gain on securities:
|
|
|
|
|
|
|
||||||||||||
|
Unrealized gain on securities
|
1
|
|
—
|
|
1
|
|
1
|
|
—
|
|
1
|
|
||||||
|
Other comprehensive income
|
$
|
351
|
|
$
|
(64
|
)
|
$
|
287
|
|
$
|
222
|
|
$
|
(62
|
)
|
$
|
160
|
|
|
|
March 31, 2012
|
December 31, 2011
|
||||
|
Derivatives designated as hedging instruments:
|
|
|
||||
|
Interest rate swaps
|
$
|
1,000
|
|
$
|
1,000
|
|
|
Foreign currency contracts
|
2,377
|
|
2,032
|
|
||
|
Commodity contracts
|
334
|
|
553
|
|
||
|
Derivatives not designated as hedging instruments:
|
|
|
||||
|
Foreign currency contracts
|
7,382
|
|
6,444
|
|
||
|
Commodity contracts
|
224
|
|
437
|
|
||
|
|
Three Months Ended
|
|||||
|
|
March 31,
|
|||||
|
|
2012
|
2011
|
||||
|
Beginning balance
|
$
|
41
|
|
$
|
(31
|
)
|
|
Net revaluation and clearance of cash flow hedges to earnings
|
(23
|
)
|
22
|
|
||
|
Ending balance
|
$
|
18
|
|
$
|
(9
|
)
|
|
|
|
Fair Value Using Level 2 Inputs
|
|||||
|
|
Balance Sheet Location
|
March 31,
2012
|
December 31, 2011
|
||||
|
Asset derivatives:
|
|
|
|
||||
|
Derivatives designated as hedging instruments:
|
|
|
|
||||
|
Interest rate swaps
|
Other assets
|
$
|
63
|
|
$
|
66
|
|
|
Foreign currency contracts
|
Accounts and notes receivable, net
|
31
|
|
44
|
|
||
|
|
|
94
|
|
110
|
|
||
|
Derivatives not designated as hedging instruments:
|
|
|
|
||||
|
Foreign currency contracts
|
Accounts and notes receivable, net
|
95
|
|
100
|
|
||
|
Foreign currency contracts
|
Other assets
|
34
|
|
43
|
|
||
|
|
|
129
|
|
143
|
|
||
|
Total asset derivatives
|
|
$
|
223
|
|
$
|
253
|
|
|
Liability derivatives:
|
|
|
|
||||
|
Derivatives designated as hedging instruments:
|
|
|
|
||||
|
Foreign currency contracts
|
Other accrued liabilities
|
$
|
7
|
|
$
|
12
|
|
|
Commodity contracts
|
Other accrued liabilities
|
—
|
|
1
|
|
||
|
|
|
7
|
|
13
|
|
||
|
Derivatives not designated as hedging instruments:
|
|
|
|
||||
|
Foreign currency contracts
|
Other accrued liabilities
|
48
|
|
21
|
|
||
|
Commodity contracts
|
Other accrued liabilities
|
2
|
|
2
|
|
||
|
|
|
50
|
|
23
|
|
||
|
Total liability derivatives
|
|
$
|
57
|
|
$
|
36
|
|
|
|
Amount of Gain (Loss)
Recognized in OCI
1
(Effective Portion)
|
Amount of Gain (Loss)
Recognized in Income
2
|
|
||||||||||
|
Three Months Ended March 31,
|
2012
|
2011
|
2012
|
2011
|
Income Statement Classification
|
||||||||
|
Derivatives designated as hedging instruments:
|
|
|
|
|
|
||||||||
|
Fair value hedges:
|
|
|
|
|
|
||||||||
|
Interest rate swaps
|
$
|
—
|
|
$
|
—
|
|
$
|
(3
|
)
|
$
|
(10
|
)
|
Interest expense
3
|
|
Cash flow hedges:
|
|
|
|
|
|
||||||||
|
Foreign currency contracts
|
(10
|
)
|
(21
|
)
|
3
|
|
(5
|
)
|
Net sales
|
||||
|
Commodity contracts
|
6
|
|
30
|
|
29
|
|
(22
|
)
|
COGS
4
|
||||
|
|
(4
|
)
|
9
|
|
29
|
|
(37
|
)
|
|
||||
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
|
||||||||
|
Foreign currency contracts
|
—
|
|
—
|
|
(128
|
)
|
(373
|
)
|
Other income, net
5
|
||||
|
Commodity contracts
|
—
|
|
—
|
|
(11
|
)
|
1
|
|
COGS
4
|
||||
|
|
—
|
|
—
|
|
(139
|
)
|
(372
|
)
|
|
||||
|
Total derivatives
|
$
|
(4
|
)
|
$
|
9
|
|
$
|
(110
|
)
|
$
|
(409
|
)
|
|
|
1
|
OCI is defined as other comprehensive income (loss).
|
|
2
|
For cash flow hedges, this represents the effective portion of the gain (loss) reclassified from accumulated OCI into income during the period. For the three months ended
March 31, 2012
and 2011, there was no material ineffectiveness with regard to the company's cash flow hedges.
|
|
3
|
Gain (loss) recognized in income of derivative is offset to
$0
by gain (loss) recognized in income of the hedged item.
|
|
4
|
COGS is defined as costs of goods sold and other operating charges.
|
|
5
|
Gain (loss) recognized in other income, net, was partially offset by the related gain (loss) on the foreign currency-denominated monetary assets and liabilities of the company's operations, which were
$48
and
$230
for the three months ended
March 31, 2012
and 2011, respectively.
|
|
|
Three Months Ended
|
|||||
|
|
March 31,
|
|||||
|
|
2012
|
2011
|
||||
|
Service cost
|
$
|
68
|
|
$
|
59
|
|
|
Interest cost
|
297
|
|
310
|
|
||
|
Expected return on plan assets
|
(381
|
)
|
(365
|
)
|
||
|
Amortization of unrecognized loss
|
219
|
|
153
|
|
||
|
Amortization of prior service cost
|
4
|
|
4
|
|
||
|
Net periodic benefit cost
|
$
|
207
|
|
$
|
161
|
|
|
|
Three Months Ended
|
|||||
|
|
March 31,
|
|||||
|
|
2012
|
2011
|
||||
|
Service cost
|
$
|
9
|
|
$
|
8
|
|
|
Interest cost
|
48
|
|
53
|
|
||
|
Amortization of unrecognized loss
|
22
|
|
15
|
|
||
|
Amortization of prior service benefit
|
(30
|
)
|
(30
|
)
|
||
|
Net periodic benefit cost
|
$
|
49
|
|
$
|
46
|
|
|
Three Months Ended
March 31,
|
Agriculture
1
|
Electronics &
Communications
|
Industrial Biosciences
|
Nutrition & Health
|
Performance
Chemicals
|
Performance
Coatings
|
Performance
Materials
|
Safety &
Protection
|
Pharm-aceuticals
|
Other
|
Total
|
||||||||||||||||||||||||||||||||
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Segment sales
|
$
|
4,080
|
|
|
$
|
677
|
|
|
$
|
288
|
|
|
$
|
808
|
|
|
$
|
1,900
|
|
|
$
|
1,050
|
|
|
$
|
1,600
|
|
|
$
|
941
|
|
|
$
|
—
|
|
|
$
|
1
|
|
|
$
|
11,345
|
|
|
Less: Transfers
|
2
|
|
|
4
|
|
|
3
|
|
|
—
|
|
|
77
|
|
|
—
|
|
|
26
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|
115
|
|
|||||||||||
|
Net sales
|
4,078
|
|
|
673
|
|
|
285
|
|
|
808
|
|
|
1,823
|
|
|
1,050
|
|
|
1,574
|
|
|
938
|
|
|
—
|
|
|
1
|
|
|
11,230
|
|
|||||||||||
|
PTOI
|
1,264
|
|
2
|
33
|
|
|
41
|
|
|
83
|
|
|
512
|
|
|
87
|
|
|
240
|
|
|
100
|
|
|
27
|
|
|
(60
|
)
|
|
2,327
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Segment sales
|
$
|
3,504
|
|
|
$
|
811
|
|
|
$
|
—
|
|
|
$
|
324
|
|
|
$
|
1,797
|
|
|
$
|
993
|
|
|
$
|
1,707
|
|
|
$
|
965
|
|
|
$
|
—
|
|
|
$
|
36
|
|
|
$
|
10,137
|
|
|
Less: Transfers
|
—
|
|
|
5
|
|
|
—
|
|
|
—
|
|
|
67
|
|
|
—
|
|
|
28
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|
103
|
|
|||||||||||
|
Net sales
|
3,504
|
|
|
806
|
|
|
—
|
|
|
324
|
|
|
1,730
|
|
|
993
|
|
|
1,679
|
|
|
962
|
|
|
—
|
|
|
36
|
|
|
10,034
|
|
|||||||||||
|
PTOI
|
1,111
|
|
|
111
|
|
|
—
|
|
|
25
|
|
|
394
|
|
|
65
|
|
|
288
|
|
|
145
|
|
|
50
|
|
|
(64
|
)
|
|
2,125
|
|
|||||||||||
|
1
|
As of
March 31, 2012
, Agriculture net assets were
$7,509
, an increase of
$2,744
from
$4,765
at
December 31, 2011
. The increase was primarily due to higher trade receivables due to normal seasonality in the sales and cash collections cycle.
|
|
2
|
Included a
$(50)
charge recorded in cost of goods sold and other operating charges associated with the company's process to fairly resolve claims associated with the use of Imprelis
®
. See Note 7 for additional information.
|
|
|
Three Months Ended
March 31,
|
|||||
|
|
2012
|
2011
|
||||
|
Total segment PTOI
|
$
|
2,327
|
|
$
|
2,125
|
|
|
Net exchange losses, including affiliates
|
(80
|
)
|
(143
|
)
|
||
|
Corporate expenses and net interest
|
(306
|
)
|
(280
|
)
|
||
|
Income before income taxes
|
$
|
1,941
|
|
$
|
1,702
|
|
|
Item 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
|
•
|
Fluctuations in energy and raw material prices;
|
|
•
|
Failure to develop and market new products and optimally manage product life cycles;
|
|
•
|
Outcome of significant litigation and environmental matters, including those related to divested businesses;
|
|
•
|
Failure to appropriately manage process safety and product stewardship issues;
|
|
•
|
Effect of changes in tax, environmental and other laws and regulations or political conditions in the United States of America (U.S.) and other countries in which the company operates;
|
|
•
|
Conditions in the global economy and global capital markets, including economic factors, such as inflation, deflation and fluctuations in currency exchange rates, interest rates and commodity prices, as well as regulatory requirements;
|
|
•
|
Impact of business disruptions, including supply disruptions, and security threats, regardless of cause, including acts of sabotage, terrorism or war, weather events and natural disasters;
|
|
•
|
Inability to protect and enforce the company's intellectual property rights; and
|
|
•
|
Successful integration of acquired businesses and completion of divestitures of underperforming or non-strategic assets or businesses.
|
|
•
|
First quarter 2012 earnings were $1.57 per share versus $1.52 per share in 2011.
|
|
•
|
Sales of $11.2 billion were up 12 percent including a 7 percent net sales increase from portfolio changes. Volume, down 2 percent compared to the same period last year, showed sequential improvement in industrial markets, which includes titanium dioxide, indicating a positive shift in momentum heading into the second quarter 2012. Sales in developing markets
1
grew 15 percent, led by growth in Agriculture.
|
|
•
|
Segment pre-tax operating income increased $202 million, or 10 percent versus the prior year, principally due to gains in Agriculture, Performance Chemicals and the benefit of prior-year acquisitions in Nutrition & Health and Industrial Biosciences.
|
|
•
|
Agriculture delivered 16 percent higher sales and a 14 percent increase in pre-tax operating income versus last year’s first quarter. This reflects strong global business performance and an early start to the North American and European selling seasons, which increased first quarter 2012 earnings about $0.03 per share.
|
|
•
|
DuPont continues to achieve fixed cost, working capital and variable cost productivity through disciplined business processes called DuPont Integrated Business Management and DuPont Production Systems. The company remains on track with productivity initiatives achieving improvements of approximately $100 million for both fixed costs and working capital in the first quarter 2012.
|
|
1
|
Developing markets include China, India and countries located in Latin America, Eastern and Central Europe, Middle East, Africa and Southeast Asia.
|
|
|
Three Months Ended
March 31, 2012
|
|
Percent Change Due to:
|
||||||||||
|
|
Net Sales
($ Billions)
|
Percent
Change vs.
2011
|
Local
Price
|
Currency
Effect
|
Volume
|
Portfolio
|
|||||||
|
Worldwide
|
$
|
11.2
|
|
12
|
|
8
|
|
(1
|
)
|
(2
|
)
|
7
|
|
|
U.S. & Canada
|
4.8
|
|
13
|
|
9
|
|
—
|
|
—
|
|
4
|
|
|
|
Europe, Middle East & Africa (EMEA)
|
3.2
|
|
14
|
|
8
|
|
(3
|
)
|
(1
|
)
|
10
|
|
|
|
Asia Pacific
|
2.0
|
|
—
|
|
4
|
|
1
|
|
(13
|
)
|
8
|
|
|
|
Latin America
|
1.2
|
|
23
|
|
15
|
|
(3
|
)
|
4
|
|
7
|
|
|
|
|
Three Months Ended
|
|
|
|
||||||
|
|
March 31, 2012
|
Percentage Change Due to:
|
||||||||
|
|
Segment
Sales
($ Billions)
|
Percent
Change vs.
2011
|
Selling
Price
|
Volume
|
Portfolio
and Other
|
|||||
|
Agriculture
|
$
|
4.1
|
|
16
|
|
8
|
8
|
|
—
|
|
|
Electronics & Communications
|
0.7
|
|
(17
|
)
|
1
|
(18
|
)
|
—
|
|
|
|
Industrial Biosciences
|
0.3
|
|
nm
|
|
nm
|
nm
|
|
nm
|
|
|
|
Nutrition & Health
|
0.8
|
|
149
|
|
—
|
(5
|
)
|
154
|
|
|
|
Performance Chemicals
|
1.9
|
|
6
|
|
16
|
(10
|
)
|
—
|
|
|
|
Performance Coatings
|
1.1
|
|
6
|
|
6
|
—
|
|
—
|
|
|
|
Performance Materials
|
1.6
|
|
(6
|
)
|
6
|
(10
|
)
|
(2
|
)
|
|
|
Safety & Protection
|
0.9
|
|
(2
|
)
|
3
|
(5
|
)
|
—
|
|
|
|
(Dollars in millions)
|
March 31, 2012
|
December 31, 2011
|
||||
|
Cash, cash equivalents and marketable securities
|
$
|
3,601
|
|
$
|
4,019
|
|
|
Total debt
|
14,825
|
|
12,553
|
|
||
|
|
Long-term
|
Short-term
|
Outlook
|
|
Standard & Poor's
|
A
|
A-1
|
Stable
|
|
Moody’s Investors Service
|
A2
|
P-1
|
Stable
|
|
Fitch Ratings
|
A
|
F1
|
Stable
|
|
|
Three Months Ended
|
|||||
|
|
March 31,
|
|||||
|
(Dollars in millions)
|
2012
|
2011
|
||||
|
Cash used for operating activities
|
$
|
(1,877
|
)
|
$
|
(1,484
|
)
|
|
Purchases of property, plant and equipment
|
(301
|
)
|
(323
|
)
|
||
|
Free cash flow
|
$
|
(2,178
|
)
|
$
|
(1,807
|
)
|
|
Item 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
|
Item 1.
|
LEGAL PROCEEDINGS
|
|
Item 6.
|
EXHIBITS
|
|
|
E. I. DU PONT DE NEMOURS AND COMPANY
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
Date:
|
April 24, 2012
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/Nicholas C. Fanandakis
|
|
|
|
|
|
|
|
Nicholas C. Fanandakis
|
|
|
|
Executive Vice President and
|
|
|
|
Chief Financial Officer
|
|
|
|
(As Duly Authorized Officer and
|
|
|
|
Principal Financial and Accounting Officer)
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
3.1
|
|
Company’s Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the company’s Annual Report on Form 10-K for the year ended December 31, 2007).
|
|
|
|
|
|
3.2
|
|
Company’s Bylaws, as last amended effective November 1, 2009 (incorporated by reference to Exhibit 3.2 to the company’s Annual Report on Form 10-K for the year ended December 31, 2009).
|
|
|
|
|
|
4
|
|
The company agrees to provide the Commission, on request, copies of instruments defining the rights of holders of long-term debt of the company and its subsidiaries.
|
|
|
|
|
|
10.1*
|
|
The DuPont Stock Accumulation and Deferred Compensation Plan for Directors, as last amended effective January 1, 2009 (incorporated by reference to Exhibit 10.1 to the company’s Annual Report on Form 10-K for the year ended December 31, 2008).
|
|
|
|
|
|
10.2*
|
|
Company’s Supplemental Retirement Income Plan, as last amended effective June 4, 1996 (incorporated by reference to Exhibit 10.2 to the company’s Annual Report on Form 10-K for the year ended December 31, 2011).
|
|
|
|
|
|
10.3*
|
|
Company’s Pension Restoration Plan, as restated effective July 17, 2006 (incorporated by reference to Exhibit 10.3 to the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2011).
|
|
|
|
|
|
10.4*
|
|
Company’s Rules for Lump Sum Payments, as last amended effective December 20, 2007 (incorporated by reference to Exhibit 10.4 to the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2011).
|
|
|
|
|
|
10.5*
|
|
Company’s Stock Performance Plan, as last amended effective January 25, 2007(incorporated by reference to Exhibit 10.5 to the company’s Annual Report on Form 10-K for the year ended December 31, 2011).
|
|
|
|
|
|
10.6*
|
|
Company’s Equity and Incentive Plan as amended and restated effective March 2, 2011 and approved by the company’s shareholders on April 27, 2011 (incorporated by reference to pages B1-B15 of the company’s Annual Meeting Proxy Statement dated March 18, 2011).
|
|
|
|
|
|
10.7*
|
|
Form of Award Terms under the company’s Equity and Incentive Plan (incorporated by reference to Exhibit 10.8 to the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2009).
|
|
|
|
|
|
10.8*
|
|
Company’s Retirement Savings Restoration Plan, as last amended effective June 1, 2011 (incorporated by reference to Exhibit 10.8 to the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2011).
|
|
|
|
|
|
10.9*
|
|
Company’s Retirement Income Plan for Directors, as last amended January 2011.
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
10.10*
|
|
Company’s Management Deferred Compensation Plan, adopted on May 2, 2008, as last amended May 12, 2010 (incorporated by reference to Exhibit 10.11 to the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2010).
|
|
|
|
|
|
10.11*
|
|
Supplemental Deferral Terms for Deferred Long Term Incentive Awards and Deferred Variable Compensation Awards (incorporated by reference to Exhibit 10.15 to the company’s Annual Report on Form 10-K for the year ended December 31, 2008).
|
|
|
|
|
|
12
|
|
Computation of Ratio of Earnings to Fixed Charges.
|
|
|
|
|
|
31.1
|
|
Rule 13a-14(a)/15d-14(a) Certification of the company’s Principal Executive Officer.
|
|
|
|
|
|
31.2
|
|
Rule 13a-14(a)/15d-14(a) Certification of the company’s Principal Financial Officer.
|
|
|
|
|
|
32.1
|
|
Section 1350 Certification of the company’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
|
|
|
|
|
|
32.2
|
|
Section 1350 Certification of the company’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
|
|
|
|
|
|
95
|
|
Mine Safety Disclosures.
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|